BridgeBio Pharma Inc [BBIO] stock is trading at $47.27, up 3.62%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BBIO shares have gain 3.53% over the last week, with a monthly amount glided 10.50%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Truist started tracking the stock with Buy rating on July 21, 2025, and set its price target to $66. On July 14, 2025, Jefferies initiated with a Buy rating and assigned a price target of $70 on the stock. Oppenheimer upgraded its rating to a Outperform but stick to its price target of $60 on July 09, 2025. Wolfe Research initiated its recommendation with a Outperform and recommended $49 as its price target on June 17, 2025. Redburn Atlantic started tracking with a Buy rating for this stock on March 31, 2025, and assigned it a price target of $50. In a note dated October 16, 2024, Scotiabank initiated an Sector Outperform rating.
BridgeBio Pharma Inc [BBIO] stock has fluctuated between $21.72 and $48.68 over the past year. Currently, Wall Street analysts expect the stock to reach $72 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $47.27 at the most recent close of the market. An investor can expect a potential return of 52.32% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
BridgeBio Pharma Inc [NASDAQ:BBIO] reported sales of 127.42M for the trailing twelve months, which represents a drop of -44.76%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -5.48%, Pretax Profit Margin comes in at -5.29%, and Net Profit Margin reading is -5.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.76, Equity is 0.49 and Total Capital is -0.96. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 45.86 points at the first support level, and at 44.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.37, and for the 2nd resistance point, it is at 49.47.
Ratios To Look Out For
For context, BridgeBio Pharma Inc’s Current Ratio is 4.57. In addition, the Quick Ratio stands at 4.54 and the Cash Ratio stands at 3.55. Considering the valuation of this stock, the price to sales ratio is 70.44.
Transactions by insiders
Recent insider trading involved Kumar Neil, Chief Executive Officer, that happened on Jul 02 ’25 when 40000.0 shares were sold. Chief Executive Officer, Kumar Neil completed a deal on Jul 01 ’25 to sell 40000.0 shares. Meanwhile, 10% Owner VIKING GLOBAL INVESTORS LP sold 3.5 million shares on Jun 27 ’25.
